

R Touhey Myer (NJ Bar ID 028912009)  
**KRATZ & BARRY LLP**  
800 N. West Street  
Wilmington, DE 19801  
(302) 527-9378  
tmyer@kratzandbarry.com

*Of Counsel:*

Timothy H. Kratz (*Pro Hac Vice*)  
George J. Barry III (*Pro Hac Vice Expected*)  
John Thallemer (*Pro Hac Vice Expected*)  
**KRATZ & BARRY LLP**  
1050 Crown Pointe Parkway, Suite 500  
Atlanta, GA 30338  
(404) 431-6600  
tkratz@kratzandbarry.com  
gbarry@kratzandbarry.com

Michael P. Hogan (*Pro Hac Vice*)  
**KRATZ & BARRY LLP**  
622 South 4th Street  
P.O. Box 63765  
Philadelphia, PA 19147  
(917) 216-8585  
mhogan@kratzandbarry.com

*Attorneys for Defendant/Counterclaim  
Plaintiff, Gland Pharma Limited*

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF NEW JERSEY**

---

IN RE SELENIOUS ACID LITIGATION

:  
:  
:  
:  
:  
:  
:

Hon. Brian R. Martinotti, U.S.D.J.

C.A. No. 2:24-cv-07791-BRM-CLW

(Consolidated)

---

**DEFENDANT/COUNTERCLAIM PLAINTIFF,  
GLAND PHARMA LIMITED'S ANSWER TO COMPLAINT FOR  
PATENT INFRINGEMENT, AFFIRMATIVE DEFENSES, AND COUNTERCLAIMS**

Defendant Gland Pharma Limited ("Gland" or "Defendant"), by and through its undersigned attorneys, hereby respectfully responds to the Complaint filed by Plaintiff American Regent, Inc. ("ARI," or "Plaintiff") as follows:

**Responses to Allegations Pertaining to the Nature of the Action**

1. This is an action for patent infringement under the patent laws of the United States, 35 U.S.C. § 100 *et. seq.*, arising from Gland Pharma's submission to the United States Food and Drug Administration ("FDA") of Abbreviated New Drug Application No. 219629 ("the ANDA") which contains a certification of the type described in Section 505(j)(2)(A)(vii)(IV) of

the Federal Food, Drug, and Cosmetic Act (“Paragraph IV Certification”) seeking approval to engage in the commercial manufacture, use, sale, and/or importation of a generic version of ARI’s Selenious Acid products (“the ANDA Product”) prior to the expiration of United States Patent No. 12,150,957 (“the ’957 patent” or the “Asserted Patent”). As discussed below, this case involves the same ANDA No. 219629 and thus is a related case to *American Regent, Inc. v. Gland Pharma Limited*, C.A. No. 24-7802 (D.N.J.) (the “Related Action”).

**RESPONSE:** Gland admits Plaintiff purports to bring this action for alleged patent infringement under the patent laws of the United States, 35 U.S.C. § 100 *et seq.* Gland admits filing ANDA No. 219629 and supplementing the same with a Paragraph IV Certification pertaining to the ’957 patent. Gland admits this case is related to *American Regent, Inc. v. Gland Pharma Limited*, C.A. No. 24-7802 (D.N.J.) (the “Related Action”) as it involves the same ANDA No. 219629. Gland denies all further allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

### **Responses to Allegations Pertaining to The Parties**

2. ARI is a corporation organized and existing under the laws of the State of New York, with a principal place of business at 5 Ramsey Road, Shirley, New York 11967.

**RESPONSE:** Gland is without knowledge or information sufficient to form a belief as to the truth of the allegations in this paragraph of the Complaint and, therefore, denies the same. Allegations not expressly admitted are denied.

3. On information and belief, Gland Pharma is a corporation organized and existing under the laws of India with its principal place of business at Survey No. 143-148, 150 & 151 Near Gandimaisamma ‘X’ Roads D.P. Pally, Dundigal Gandimaisamma Mandal MedchalMalkjgiri District, Hyderabad 500043, Telangana, India.

**RESPONSE:** Gland admits it is organized and existing under the laws of the Republic of India with a place of business at Survey No. 143-148, 150 & 151 Near Gandimaisamma ‘X’ Roads D.P. Pally, Dundigal Gandimaisamma Mandal MedchalMalkjgiri District, Hyderabad 500043, Telangana, India. Gland denies all remaining allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

**Responses to Allegations Pertaining to Jurisdiction**

4. This is a civil action for patent infringement arising under the patent laws of the United States, 35 U.S.C. § 100 *et. seq.*, and jurisdiction is proper under 28 U.S.C. §§ 1331, 1338(a), 2201, and 2202.

**RESPONSE:** Gland admits the Court has subject matter jurisdiction pursuant to 28 U.S.C. §§ 1331, 1338(a), 2201, and 2202. Gland denies all further allegations remaining in this paragraph of the Complaint. Allegations not expressly admitted are denied.

5. On information and belief, this Court has personal jurisdiction over Gland Pharma under the New Jersey state long arm statute and consistent with due process of law because Gland Pharma has extensive contacts with the State of New Jersey and regularly does business in this judicial district. Further, Gland Pharma plans to sell the ANDA Product in the State of New Jersey, which provides an independent basis for personal jurisdiction here.

**RESPONSE:** Solely for the purpose of this litigation, Gland does not contest the Court's exercise of personal jurisdiction over Gland. Gland denies all allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

6. This Court has personal jurisdiction over Gland Pharma because Gland Pharma has purposefully availed itself of the rights and benefits of New Jersey law by engaging in systematic and continuous contact with the State of New Jersey. On information and belief, Gland Pharma regularly and continuously transacts business within New Jersey, including by making pharmaceutical products for sale in New Jersey and selling pharmaceutical products in New Jersey. On information and belief, Gland Pharma derives substantial revenue from the sale of those products in New Jersey and has availed itself of the privilege of conducting business within New Jersey. On information and belief, Gland Pharma derives substantial revenue from selling generic pharmaceutical products and/or pharmaceutical ingredient(s) used in generic pharmaceutical products sold throughout the United States, including in this judicial district.

**RESPONSE:** Solely for the purpose of this litigation, Gland does not contest the Court's exercise of personal jurisdiction over Gland. Gland denies all allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

7. This Court has personal jurisdiction over Gland Pharma because, on information and belief, Gland Pharma derives substantial revenue from directly or indirectly selling generic pharmaceutical products and/or pharmaceutical ingredient(s) used in generic pharmaceutical products sold throughout the United States, including in this judicial district.

**RESPONSE:** Solely for the purpose of this litigation, Gland does not contest the Court's exercise of personal jurisdiction over Gland. Gland denies all allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

8. Upon information and belief, Gland Pharma is in the business of, among other things, the development, manufacturing, importation, marketing, sale, and distribution of generic pharmaceutical products throughout the United States, including in this judicial district. Gland Pharma's website states that Gland Pharma has "a global footprint across 60 countries, including the United States," with a "focus on complex injectables including NCE-1s, First-to-File products and 505(b)(2) filings."

**RESPONSE:** Solely for the purpose of this litigation, Gland does not contest the Court's exercise of personal jurisdiction over Gland. Gland denies all allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

9. This Court has personal jurisdiction over Gland Pharma because, inter alia, Gland Pharma has committed an act of patent infringement under 35 U.S.C. § 271(e)(2) and intends a future course of conduct that includes acts of patent infringement in New Jersey. These acts have led and will lead to foreseeable harm and injury to ARI in New Jersey. Further, on information and belief, following approval of the ANDA, Gland Pharma will make, use, import, sell, and/or offer for sale the ANDA Product in the United States, including in New Jersey, prior to the expiration of the Asserted patent.

**RESPONSE:** Solely for the purpose of this litigation, Gland does not contest the Court's exercise of personal jurisdiction over Gland. Gland denies all allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

10. On information and belief, this Court also has personal jurisdiction over Gland Pharma because it has previously availed itself of the legal protections of the State of New Jersey by, among other things, not contesting jurisdiction in this judicial district, and pursuing counterclaims in this judicial district, including in at least Merck Sharp & Dohme LLC v. Gland Pharma Limited, No. 22-05461, ECF No. 12 (D.N.J. Mar. 6, 2023).

**RESPONSE:** Solely for the purpose of this litigation, Gland does not contest the Court's exercise of personal jurisdiction over Gland. Gland denies all allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

11. In the alternative, this Court has personal jurisdiction over Gland Pharma because the requirements of Federal Rule of Civil Procedure 4(k)(2)(A) are met as (a) ARI's claims arise under federal law; (b) Gland Pharma is a foreign defendant not subject to general personal jurisdiction in the courts of any state; and (c) Gland Pharma has sufficient contacts with the United States as a whole, including, but not limited to, preparing and submitting the ANDA to the FDA and/or manufacturing and/or selling pharmaceutical products distributed throughout the United States, such that this Court's exercise of jurisdiction over Gland Pharma satisfies due process.

**RESPONSE:** Solely for the purpose of this litigation, Gland does not contest the Court's exercise of personal jurisdiction over Gland. Gland denies all allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

12. Venue is further proper in this Court under 28 U.S.C. §§ 1391 and/or 1400(b).

**RESPONSE:** Solely for the purpose of this litigation, Gland does not contest venue in this Court. Gland denies all allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

13. On information and belief, venue is proper in this judicial district under 28 U.S.C. 1391(c)(3) because Gland Pharma is a foreign company not residing in any United States judicial district and may be sued in any judicial district.

**RESPONSE:** Solely for the purpose of this litigation, Gland does not contest venue in this Court. Gland denies all allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

**Responses to Allegations Pertaining to the Factual Background**

14. ARI holds New Drug Application ("NDA") No. 209379 for Selenious Acid ((1) eq. 600 mcg Selenium/10 mL (eq. 60 mcg Selenium/mL), (2) eq. 60 mcg Selenium/mL (eq. 60 mcg Selenium/mL), and (3) eq. 12 mcg Selenium/2 mL (eq. 6 mcg Selenium/mL)), which was originally approved by the FDA on April 30, 2019, which ARI manufactures and sells in this judicial district and throughout the United States.

**RESPONSE:** On information and belief, Gland admits Plaintiff ARI is the holder of NDA No. 209379 approved by the FDA. Gland is without knowledge or information sufficient to form a

belief as to the truth of the remaining allegations in this paragraph of the Complaint and, therefore, denies the same. Allegations not expressly admitted are denied.

15. The use of ARI's Selenious Acid products is covered by one or more claims of the Asserted Patent.

**RESPONSE:** Gland is without knowledge or information sufficient to form a belief as to the truth of the allegations in this paragraph of the Complaint and, therefore, denies the same. Allegations not expressly admitted are denied.

16. ARI is the owner of the '957 patent, entitled "Trace element compositions, methods of making and use," which was duly and legally issued on November 26, 2024. A copy of the '957 patent is attached as Exhibit A.

**RESPONSE:** Gland admits Exhibit A to the Complaint appears to be a copy of the '957 patent, which Gland admits is titled "Trace element compositions, methods of making and use." Gland admits the face of the '957 patent states the '957 patent issued November 26, 2024. Gland denies all further allegations remaining in this paragraph of the Complaint. Allegations not expressly admitted are denied.

17. The '957 patent has been listed in connection with ARI's Selenious Acid products in the FDA's publication Approved Drug Products with Therapeutic Equivalence Evaluations (the "Orange Book").

**RESPONSE:** Gland admits the '957 patent is listed in the Orange Book in connection with NDA No. 209379. Gland denies all further allegations remaining in this paragraph of the Complaint. Allegations not expressly admitted are denied.

18. As indicated in the Orange Book, the patent expiration date for the '957 patent is July 1, 2041.

**RESPONSE:** Gland admits the Orange Book indicates that the '957 patent expires on July 1, 2041. Allegations not expressly admitted are denied.

19. On information and belief, Gland Pharma was responsible for preparing the ANDA which contained a Paragraph IV Certification.

**RESPONSE:** Gland admits preparing and filing Gland’s ANDA and that its ANDA contains a Paragraph IV Certification. Gland denies all remaining allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

20. By letter dated June 10, 2024 (“the Notice Letter”), Gland Pharma notified ARI that, pursuant to the Federal Food, Drug, and Cosmetic Act, Gland Pharma had submitted the ANDA with a Paragraph IV Certification to the FDA seeking approval to engage in the commercial manufacture, use, offer for sale, sale, and/or importation of the ANDA Product prior to the expiration of U.S. Patent No. 11,998,565 (“the ’565 patent”), which is at issue in the Related Action.

**RESPONSE:** Gland admits that it properly notified ARI that it had submitted the ANDA with a Paragraph IV Certification with respect to the ’565 patent by letter dated June 11, 2024. Gland denies all remaining allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

21. On information and belief, Gland Pharma submitted the ANDA to the FDA, which contained a Paragraph IV Certification asserting that the ’565 patent will not be infringed by the manufacture, use, offer for sale, sale, or importation of the ANDA Product, or alternatively, that the ’565 patent is invalid.

**RESPONSE:** Admitted.

22. Since ARI received the Notice Letter and filed its complaint against Gland in the Related Action, the ’957 patent has been listed in connection with ARI’s Selenious Acid products in the Orange Book.

**RESPONSE:** Admitted.

23. On information and belief, the ANDA Product is a generic version of ARI’s Selenious Acid products ((1) eq. 600mcg Selenium/10mL (eq. 60 mcg Selenium/mL)), as its reference listed drug, containing the same or equivalent ingredients in the same or equivalent amounts.

**RESPONSE:** Denied.

24. In the Notice Letter, Gland Pharma disclosed that the ANDA Product is selenious acid (trace elements injection selenious acid, USP) in 10 mL pharmacy bulk package vial.

**RESPONSE:** Admitted.



25. On information and belief, the ANDA Product contains selenious acid in the same or equivalent amounts as ARI's Selenious Acid products ((1) eq. 600 mcg Selenium/10 mL (eq. 60 mcg Selenium/mL)).

**RESPONSE:** Denied.

26. On information and belief, the ANDA Product will feature the same or equivalent chemical and therapeutic properties as ARI's Selenious Acid products.

**RESPONSE:** Denied.

### **COUNT I: INFRINGEMENT OF THE '957 PATENT**

27. ARI realleges paragraphs 1–26 as if fully set forth herein.

**RESPONSE:** Defendants incorporate each of the preceding paragraphs as if fully set forth herein.

28. Gland Pharma's submission of the ANDA with a Paragraph IV Certification to obtain approval to engage in the commercial manufacture, use, offer for sale, sale and/or importation of the ANDA Product in or into the United States, prior to the expiration of the '957 patent, constitutes direct and indirect infringement of the '957 patent pursuant to 35 U.S.C. § 271(e)(2)(A), either literally or under the doctrine of equivalents.

**RESPONSE:** Denied.

29. On information and belief, the ANDA Product, if approved by the FDA, will be manufactured, used, offered for sale, sold, and/or imported in or into the United States by Gland Pharma or on its behalf, and will be administered by patients and/or medical practitioners in the United States according to the directions and instructions in the proposed package insert, which will constitute direct infringement by patients and/or medical practitioners of one or more claims of the '565 patent, under 35 U.S.C. § 271(a), either literally or under the doctrine of equivalents. On information and belief, the administration of the ANDA Product will occur with Gland Pharma's specific intent and encouragement, and will constitute conduct that Gland Pharma knows or should know will occur. On information and belief, Gland Pharma will actively induce, encourage, aid, and abet that conduct by patients and/or medical practitioners, with knowledge and specific intent that the conduct will be in contravention of ARI's rights under the '957 patent.

**RESPONSE:** Denied.

30. On information and belief, Gland Pharma's manufacture, use, offer for sale, sale, and/or importation of the ANDA Product, once the ANDA with a Paragraph IV Certification is approved by the FDA, would constitute direct infringement under 35 U.S.C. § 271(a), induced infringement under 35 U.S.C. § 271(b), and/or contributory infringement under 35 U.S.C. § 271(c) of one or more claims of the '957 patent, either literally or under the doctrine of equivalents. On information and belief, Gland Pharma intends that the ANDA Product be used by patients and



medical professionals. Also, on information and belief, Gland Pharma knows that the ANDA Product is especially made or adapted for use in infringing the '957 patent, and that the ANDA Product is not suitable for substantial non-infringing use.

**RESPONSE:** Denied.

31. ARI will be irreparably harmed if Gland Pharma is permitted to make, use, sell, offer to sell, and/or import the ANDA Product in or into the United States, and is not enjoined from doing so. ARI is entitled to relief provided by 35 U.S.C. §§ 271(e)(4) and/or 283, including an order of this Court that the effective date of approval of the ANDA be a date that is not earlier than the expiration date of the '957 patent, or any later expiration of exclusivity for the '957 patent to which ARI is or becomes entitled, and an injunction against such infringement. ARI does not have an adequate remedy at law.

**RESPONSE:** Denied.

32. Gland Pharma has had knowledge of the '957 patent since at least the date Gland Pharma submitted the ANDA with a Paragraph IV Certification and was aware that submission of the ANDA with a Paragraph IV Certification constituted an act of infringement under 35 U.S.C. § 271(e)(2).

**RESPONSE:** Denied.

33. This case is “exceptional,” and ARI is entitled to an award of reasonable attorneys’ fees under 35 U.S.C. § 285.

**RESPONSE:** Denied.

#### **GENERAL DENIAL AND RESPONSE TO PLAINTIFF’S REQUEST FOR RELIEF**

All allegations in Plaintiff’s Complaint not expressly admitted by Gland are hereby denied. Having answered Plaintiff’s Complaint, Gland denies Plaintiff is entitled to any of the relief requested in the Complaint or any relief whatsoever.

#### **SEPARATE DEFENSES**

Without prejudice to the denials set forth in its Answer to the Complaint, and without admitting any allegations of the Complaint not expressly admitted, Gland asserts the following separate defenses to the Complaint without assuming the burden of proof on any such defense that would otherwise rest on Plaintiff.

**FIRST SEPARATE DEFENSE**

The manufacture, use, or sale, offer for sale, or importation of the product(s) that is the subject of Gland's ANDA has not infringed, does not infringe, and would not, if marketed, manufactured, used, sold, offered for sale, or imported into the United States, infringe any valid or enforceable claim of the Patents-in-Suit.

**SECOND SEPARATE DEFENSE**

Each of claim of the Patents-in-Suit is invalid as anticipated or obvious, pursuant to 35 U.S.C. §§ 102 or 103, respectively, for example, for at least the reasons set forth in Gland's Notice Letters.

**THIRD SEPARATE DEFENSE**

Each of claim of the Patent-in-Suit is invalid, pursuant to 35 U.S.C. § 112, as, for example, indefinite, not enabled and/or failing to provide adequate written description.

**FOURTH SEPARATE DEFENSE**

By virtue of the prosecution proceedings before the United States Patent and Trademark Office of the patent applications leading to the Patent-in-suit, and specifically prosecution history estoppel, Plaintiff is estopped from maintaining that any valid or enforceable claim of the Asserted Patents is infringed by the product that is the subject of Gland's ANDA.

**FIFTH SEPARATE DEFENSE**

Plaintiff has failed to state a claim upon which relief can be granted.

**SIXTH SEPARATE DEFENSE**

Any and all additional defenses and counterclaims that discovery may reveal.

WHEREFORE, Gland hereby demands judgment in its favor based on a finding of non-infringement and/or invalidity and/or unenforceability of the Patent-in-Suit, an award of all costs

and fees incurred in defense of this Action and for such other relief as the Court may deem just and proper.

### **GLAND'S COUNTERCLAIMS**

1. Pursuant to Rule 13 of the Federal Rules of Civil Procedure, Gland Pharma Limited ("Gland"), by and through its counsel, for its Counterclaim against Plaintiff, American Regent, Inc. (herein "ARI" or "Counterclaim-Defendant"), hereby states the following:

2. This is an action for a declaratory judgment of non-infringement and invalidity of the claims of U.S. Patent No. 12,150,957 (the "'957 patent" or "Counterclaim Patent-In-Suit") pursuant to the patent laws of the United States, 35 U.S.C. § 1 et seq., the Declaratory Judgment Act, 28 U.S.C. §§ 2201, 2202, and provisions of the Hatch-Waxman Act, 21 U.S.C. § 355(j)(5)(C).

3. Upon information and belief, a true and complete copy of the '957 patent is attached to the Defendant, Gland Pharma Limited's Answer to Complaint, Affirmative Defenses and Counterclaim as Exhibit A.

### **THE PARTIES**

4. Counterclaim-Plaintiff Gland Pharma Limited is a corporation organized and existing under the laws of India with a place of business at Survey No. 143-148, 150 & 151 Near Gandimaisamma 'X' Roads D.P. Pally, Dundigal Gandimaisamma Mandal MedchalMalkjgiri District, Hyderabad 500043, Telangana, India.

5. Upon information and belief, and based upon the Complaint filed in the above-referenced case, Counterclaim-Defendant, American Regent, Inc., is a corporation organized and

existing under the laws of the State of New York, with a principal place of business at 5 Ramsey Road, Shirley, New York 11967.

### **JURISDICTION**

6. This Court has subject matter jurisdiction over this Counterclaim for declaratory judgment pursuant to 28 U.S.C. §§ 1331, 1338(a), 2201 and 2202, based on an actual controversy between Counterclaim-Plaintiff, on the one hand, and the Counterclaim-Defendant on the other hand, arising under the Patent Laws of the United States, 35 U.S.C. § 1 et seq.

7. This Court has personal jurisdiction over Counterclaim-Defendant based, inter alia, on the filing by Counterclaim-Defendant of this lawsuit in this Court.

8. Venue is proper in this judicial district under 28 U.S.C. §§ 1391(b)(1) and 1400(b).

### **ORANGE BOOK LISTING OF THE COUNTERCLAIM PATENT-IN-SUIT**

9. The Hatch-Waxman Amendments to the Food, Drug and Cosmetic Act require New Drug Application (“NDA”) holders to disclose to the FDA the patent numbers and expiration dates of those patents that the holder believes claim the “drug” for which their NDA is submitted, or patents covering a “method of using such drug.” 21 U.S.C. §§ 355(b)(1)(viii) and (c)(2).

10. On information and belief, Counterclaim-Defendant holds NDA No. 209379 for selenious acid (“ARI NDA” and “ARI NDA Product,” respectively).

11. On information and belief, Counterclaim-Defendant owns and holds the exclusive right to enforce the ’957 patent.

12. On information and belief, on November 26, 2024, the U.S. Patent and Trademark Office (“PTO”) issued the ’957 patent.

13. On information and belief, pursuant to 21 U.S.C. §§ 355(b)(1), Counterclaim-Defendant caused the FDA to list the Counterclaim Patent-In-Suit in the Orange Book in connection with the ARI NDA.

14. By maintaining the listing of the Counterclaim Patent-In-Suit in the Orange Book, Counterclaim-Defendant represents to the world its intent to enforce the Counterclaim Patent-In-Suit against any person not licensed by ARI engaged in the manufacture, use, sale, or importation of selenious acid before the expiration of the Counterclaim Patent-in-Suit.

#### **GLAND'S ABBREVIATED NEW DRUG APPLICATION**

15. Gland filed ANDA No. 219629 (the "Gland ANDA") with the FDA. Gland's ANDA included a Paragraph IV Certification to the Counterclaim Patent-In-Suit, certifying that to the best of its knowledge that all of the claims of the Counterclaim Patent-In-Suit are invalid, unenforceable, and/or will not be infringed by the manufacture, use, sale, offer to sell, and/or importation of the product described in the Gland ANDA.

16. On December 20, 2024, Gland properly notified ARI that Gland had submitted the Gland ANDA to the FDA under Section 505(j) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 355(j)) as required in accordance with 21 U.S.C. § 355(j)(2)(B) ("Gland's December 20, 2024 Notice Letter"). Included with Gland's December 20, 2024 Notice Letter was an Offer of Confidential Access to Gland's ANDA in accordance with 21 U.S.C. § 355(j)(5)(C)(III).

#### **THE PRESENCE OF A CASE OR CONTROVERSY**

17. By maintaining the Orange Book listing of the Counterclaim Patent-In-Suit in connection with the ARI NDA, Counterclaim-Defendant indicates its intent to enforce the Counterclaim Patent-In-Suit.

18. By maintaining the Orange Book listing of the Counterclaim Patent-In-Suit in connection with the ARI NDA, Counterclaim-Defendant is preserving its ability to pursue Gland for a claim of infringement of the Counterclaim Patent-In-Suit at any time.

19. Resolving Gland's Counterclaim is necessary to eliminate all foreseeable potential risk that Plaintiff will later assert the Counterclaim Patent-In-Suit to try to frustrate Gland's ability to market its ANDA product.

20. There has been, and is now, an actual and justiciable controversy between Counterclaim-Plaintiff on the one hand, and Counterclaim-Defendant, on the other hand, as to whether the products disclosed in Gland's ANDA infringe the Counterclaim Patent-In-Suit, and whether any claim in the Counterclaim Patent-In-Suit is valid or enforceable.

21. In light of all the circumstances, an actual substantial and continuing justiciable controversy having sufficient immediacy and reality to warrant the issuance of a declaration of rights by the Court exists between Counterclaim-Defendant and Counterclaim-Plaintiff as to whether the claims of the Counterclaim Patent-In-Suit are invalid and/or not infringed by Counterclaim-Plaintiff.

22. This is an exceptional case entitling Gland to an award of its reasonable attorney's fees in connection with the underlying Action and this Counterclaim in accordance with 35 U.S.C. § 285.

**COUNT I**  
**(Declaratory Judgment of Non-Infringement**  
**of the Counterclaim Patent-in-Suit)**

23. Counterclaim-Plaintiff repeats and incorporates by reference Paragraphs 1-22 of the Counterclaim, above, as if fully set forth herein.

24. This counterclaim arises under the Patent Laws of the United States, 35 U.S.C. § 1 et seq., and the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. A case of actual, substantial, and continuing justiciable controversy having adverse legal interests of sufficient immediacy and reality to warrant the issuance of a declaration of rights by this Court exists between Counterclaim-Plaintiff and Counterclaim-Defendant concerning the Counterclaim Patent-In-Suit and the claims of the Counterclaim Patent-In-Suit.

25. Gland's ANDA and the product described therein do not and would not, following FDA approval, infringe any valid claim of the '957 patent either directly or indirectly.

26. Counterclaim-Plaintiff is entitled to a declaration that Gland's ANDA and the manufacture, use, offer for sale, sale, and/or importation of Gland's ANDA product does not infringe any valid claim of the '957 patent.

**COUNT II**  
**(Declaratory Judgment of Invalidity/Unenforceability**  
**of the Counterclaim Patent-in-Suit)**

27. Counterclaim-Plaintiff repeats and incorporates by reference Paragraphs 1-26 of the Counterclaim, above, as if fully set forth herein.

28. This Counterclaim arises under the Patent Laws of the United States, 35 U.S.C. § 1 et seq., and the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. A case of actual, substantial, and continuing justiciable controversy having adverse legal interests of sufficient immediacy and reality to warrant the issuance of a declaration of rights by this Court exists between the Counterclaim-Plaintiff and Counterclaim-Defendant concerning the claims of the Counterclaim Patent-In-Suit.

29. The '957 patent is invalid at least on one or more of the grounds that the '957 patent claims and the inventions described therein are anticipated by one or more prior art



references as of the time of the alleged inventions, pursuant to 35 U.S.C. § 102, would have been obvious to persons of ordinary skill in the art as of the time of the invention, pursuant to 35 U.S.C. § 103, and/or fail to satisfy the definiteness, written description and/or enablement requirements set forth in 35 U.S.C. § 112.

30. Counterclaim-Plaintiff is entitled to a declaration that the claims of the Counterclaim Patent-In-Suit are invalid under one or more provisions of 35 U.S.C. §§ 102, 103, or 112, or other judicially-created bases for invalidation/unenforceability.

### **PRAYER FOR RELIEF**

WHEREFORE, Gland prays that the Court enter judgment in its favor and against Plaintiff as follows:

a) Dismissing the Complaint with prejudice and denying each request for relief made by Plaintiff therein;

b) Declaring that the manufacture, use, sale, offer for sale, importation, and/or marketing of the Gland's ANDA Products has not infringed, does not infringe, and will not infringe, either directly or indirectly, literally or under the doctrine of equivalents, any claims of the Patent-in-Suit;

c) Declaring that the claims of the Patent-in-Suit are invalid;

d) Declaring that this is an exceptional case in favor of Gland pursuant to 35 U.S.C. § 285;

e) Declaring that Gland is the prevailing party and awarding costs, attorneys' fees, and expenses to Gland; and

f) Awarding Gland such other and further relief to which it may be entitled.

WHEREFORE, Gland hereby demands judgment in its favor based on a finding of non-infringement and/or invalidity and/or unenforceability of the Patent-in-Suit, an award of all costs

and fees incurred in defense of this Action and for such other relief as the Court may deem just and proper.

Dated: January 7, 2025

**KRATZ & BARRY LLP**

/s/ R Touhey Myer  
R Touhey Myer  
(NJ Bar ID 028912009)  
800 N. West Street  
Wilmington, DE 19801  
(302) 527-9378  
tmyer@kratzandbarry.com

*Of Counsel:*

Timothy H. Kratz (*Pro Hac Vice*)  
George J. Barry III (*Pro Hac Vice Expected*)  
John Thallemer (*Pro Hac Vice Expected*)  
KRATZ & BARRY, LLP  
1050 Crown Pointe Parkway, Suite 500  
Atlanta, GA 30338  
(404) 431-6600  
tkratz@kratzandbarry.com  
gbarry@kratzandbarry.com  
jthallemer@kratzandbarry.com

Michael P. Hogan (*Pro Hac Vice*)  
KRATZ & BARRY LLP  
622 South 4th Street  
P.O. Box 63765  
Philadelphia, PA 19147  
(917) 216-8585  
mhogan@kratzandbarry.com

*Attorneys for Defendant/Counterclaim  
Plaintiff, Gland Pharma Limited*